Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for NefeconĀ® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Oct. 27, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration…